Marinus Receives the EMA’s CHMP Positive Opinion of Ztalmy (ganaxolone) for the Adjunctive Treatment of Seizures Associated with CDKL5 Deficiency Disorder
Shots:
- The EMA’s CHMP has adopted a positive opinion recommending the approval of Ztalmy oral suspension for epileptic seizures associated with CDD in patients aged 2-17yrs.
- The application was based on the P-III (Marigold) trial evaluating Ztalmy vs PBO in 101 patients. The trial met its 1EPs & showed a median 30.7% vs 6.9% reduction in 28-day major motor seizure frequency. In the (Marigold) OLE study, a median 49.6% reduction in major motor seizure frequency for 12mos. & demonstrated efficacy, safety & tolerability
- The EC’s final decision is expected within 67 days of receipt of the CHMP opinion & will be valid to all 27 EU member states, Iceland, Norway & Liechtenstein. If Ztalmy is approved, it will be 1st treatment in the EU & will be commercialized by Orion
Ref: Marinus | Image: Marinus
Related News:- Marinus’ Ztalmy (ganaxolone) Receives the US FDA’s Approval for the Treatment of CDKL5 Deficiency Disorder
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
